DrugPatentWatch Database Preview

Details for Patent: 8,829,186

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,829,186 protect, and when does it expire?

Patent 8,829,186 protects ZYPITAMAG and is included in one NDA.

This patent has two patent family members in two countries.

Summary for Patent: 8,829,186

Title:	Method for preparation of pitavastatin and pharmaceutical acceptable salts thereof
Abstract:	The present invention discloses a compound, which is alkali or alkaline earth metal salts of pitavastatin, wherein the alkali or earth metal comprise one or more of magnesium, zinc, potassium, strontium and barium.
Inventor(s):	Dwivedi; Shriprakash Dhar (Gujarat, IN), Patel; Dhimant Jasubhai (Gujarat, IN), Shah; Alpesh Pravinchandra (Gujarat, IN), Khera; Brij (Princeton, NJ)
Assignee:	Cadila Healthcare Limited (Ahmedabad, IN)
Application Number:	13/665,932
Patent Claim Types: see list of patent claims	Use; Composition; Compound; Process;

Drugs Protected by US Patent 8,829,186

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Medicure	ZYPITAMAG	pitavastatin magnesium	TABLET;ORAL	208379-001	Jul 14, 2017		DISCN	Yes	No			Y	Y
Medicure	ZYPITAMAG	pitavastatin magnesium	TABLET;ORAL	208379-002	Jul 14, 2017		RX	Yes	No			Y	Y
Medicure	ZYPITAMAG	pitavastatin magnesium	TABLET;ORAL	208379-003	Jul 14, 2017		RX	Yes	Yes			Y	Y

Foreign Priority and PCT Information for Patent: 8,829,186

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
India	159/MUM/2010	Jan 20, 2010

International Family Members for US Patent 8,829,186

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Japan	2013516459
World Intellectual Property Organization (WIPO)	2011089623